Pfizer Stock Price, News & Analysis

Astellas Pharma announced that the European Commission approved XTANDI™ (enzalutamide) for treating metastatic hormone-sensitive prostate cancer (mHSPC). This approval follows the Phase 3 ARCHES trial, which demonstrated a 61% reduction in the risk of radiographic progression or death when enzalutamide was combined with androgen deprivation therapy. XTANDI is now the only oral treatment available in the EU for this type of advanced prostate cancer, providing a crucial therapeutic option. The approval does not affect Astellas' financial forecasts for the current fiscal year ending March 31, 2022.

Pfizer (NYSE: PFE) is set to present at the 7th Annual Truist Securities 2021 Life Sciences Summit on May 5, 2021, at 1:50 p.m. EDT. The discussion will feature Charles Triano, Senior Vice President of Investor Relations. Investors and the public can access the live webcast and archived recordings on Pfizer's investor relations website starting today. Pfizer focuses on delivering innovative therapies and vaccines to enhance patient lives and collaborates globally to improve healthcare access. More information can be found at www.pfizer.com/investors.

Pfizer Inc. (NYSE: PFE) has acquired Amplyx Pharmaceuticals, which specializes in therapies for life-threatening diseases in immunocompromised patients. The key focus of this acquisition is Amplyx's lead compound, Fosmanogepix (APX001), designed to treat invasive fungal infections. With over 1.5 million global cases annually and a high mortality rate, Fosmanogepix targets drug-resistant fungal strains, introducing a potentially novel therapeutic class. This acquisition follows Pfizer’s previous investment in Amplyx, aiming to enhance its anti-infective portfolio.

Pfizer (NYSE: PFE) has declared a 39-cent dividend for Q2 2021, payable on June 4, 2021, to shareholders on record by May 7, 2021. This marks the 330th consecutive quarterly dividend, highlighting the company's commitment to returning capital to investors. Despite Viatris' upcoming dividend declaration, Pfizer maintains its dividend rate, benefiting shareholders holding shares in both companies. CEO Albert Bourla emphasized that strong financial performance underpins their ability to deliver value to patients and shareholders alike.

Pfizer (NYSE: PFE) invites shareholders to its virtual-only 2021 Annual Meeting on April 22 at 9:00 a.m. EDT. The decision for a virtual format was made in light of ongoing COVID-19 health concerns. Shareholders will have equivalent rights to participate and can log in starting at 8:45 a.m. using their control number. Questions can be submitted in advance by 5:00 p.m. EDT on April 21. A replay of the meeting will be available for one year. For more info, visit www.meetingcenter.io/274898886.

Pfizer Inc. (NYSE: PFE) announced an extension of the FDA's priority review period for the New Drug Application (NDA) of abrocitinib, aimed at treating moderate to severe atopic dermatitis in adults and adolescents. The Prescription Drug User Fee Act (PDUFA) goal date is now set for early Q3 2021, extended by three months. Additionally, the FDA has also extended the review period for the Supplemental New Drug Applications (sNDAs) for XELJANZ® / XELJANZ® XR (tofacitinib) for active ankylosing spondylitis by three months, with the same goal date in early Q3 2021.

Pfizer Inc. (NYSE: PFE) will host a live video webcast on April 9, 2021, at 10 a.m. EDT, featuring updates on its Oncology pipeline, including therapies like LORBRENA® for lung cancer and elranatamab for multiple myeloma. Investors can access the webcast through Pfizer's investor relations website. The session will also include a live Q&A. Pfizer emphasizes its commitment to advancing healthcare and the importance of scientific innovation in developing effective therapies for serious diseases.

Pfizer and BioNTech released updated topline results from their pivotal Phase 3 study on the BNT162b2 COVID-19 vaccine, reporting a 91.3% efficacy rate in preventing symptomatic COVID-19. The vaccine showed 100% effectiveness against severe disease according to the CDC and 95.3% against severe COVID-19 per the FDA. Safety data indicated a favorable profile from over 12,000 participants monitored for at least six months post-vaccination. These results bolster plans for a Biologics License Application to the FDA.

Pfizer (PFE) and BioNTech (BNTX) announced the successful results of a Phase 3 trial for their COVID-19 vaccine BNT162b2, showing 100% efficacy in adolescents aged 12 to 15. The trial, involving 2,260 participants, indicated no COVID-19 cases in the vaccinated group compared to 18 in the placebo group. The companies intend to submit these findings for Emergency Use Authorization (EUA) modification in the US and similar requests globally. They are also advancing studies in younger children, with the goal of public vaccination before the next school year.